Table 1. Main characteristics of studies included in the meta-analysis.
| First author, publication year | MMP types | Case nationality | Dominant ethnicity | Median or mean age | Study design | Detected sample | Survival analysis | Source of HR | Maximum months of follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Li, 2016 | MMP11 | China | Asian | 65.8 | R | tissue | DSS/MFS | Reported | 175.8 |
| Minami, 2014 | MMP2 | Japan | Asian | 71 | R | serum | DSS/RFS | Reported | 166.4 |
| Demery, 2014 | MMP7 | France | Caucasian | 69 | R | serum | OS | Reported | 194.4 |
| Olsson, 2012 | MMP2 | Sweden | Caucasian | 73 | R | tissue | RFS/PFS | Reported | 192 |
| Olsson, 2012 | MMP9 | Sweden | Caucasian | 73 | R | tissue | RFS | Reported | 192 |
| Szarvas, 2011 | MMP7 | Germany | Caucasian | 65 | R | serum | OS/DSS/MFS | Reported | 148 |
| Svatek, 2010 | MMP1 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Svatek, 2010 | MMP2 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Svatek, 2010 | MMP3 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Svatek, 2010 | MMP7 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Svatek, 2010 | MMP8 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Svatek, 2010 | MMP9 | America | Caucasian | 64 | R | serum | DSS | Reported | 50 |
| Szarvas, 2010 | MMP7 | Germany | Caucasian | 65 | R | serum | OS/DSS/MFS | Reported | 196 |
| Sagara, 2010 | MMP14 | Japan | Asian | 71 | R | tissue | DSS/MFS | SC | 195 |
| Vasala, 2003 | MMP9 | Finland | Caucasian | 67 | R | tissue | OS/DSS/RFS | SC | 120 |
| Slaton, 2004 | MMP9 | America | Caucasian | 65.5 | R | tissue | DSS | Reported | 168 |
| Vasala, 2003 | MMP2 | Finland | Caucasian | 66 | R | tissue | OS/DSS/RFS | SC | 120 |
| Durkan, 2003 | MMP9 | England | Caucasian | 70 | R | tissue | DSS/PFS | Reported | 39 |
| Durkan, 2001 | MMP1 | England | Caucasian | 70 | R | urine | DSS/PFS | SC | 39 |
| Nakopoulou, 2001 | MMP3 | Greece | Caucasian | 70 | R | tissue | OS | SC | 65 |
| Hara, 2001 | MMP9 | Japan | Asian | 65 | R | tissue | RFS | SC | 39 |
| Kanayama, 1998 | MMP2 | Japan | Asian | 69.7 | R | tissue | DSS | SC | 85.8 |
| Gohji, 1998 | MMP2 | Japan | Asian | 59 | R | serum | DSS | SC | 60 |
| Gohji, 1996 | MMP3 | Japan | Asian | 57 | R | serum | DSS | SC | 100 |
Study design is described as retrospective (R); MMPs, matrix metalloproteinases.
OS, overall survival; DSS, disease-specific survival; DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; MFS, metastasis-free survival.
SC, survival curve.